MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online - 2026 Search Trends and Publicly Available Pricing Information Context

MEDVi, a telehealth platform operated by MEDVi, LLC and based in Newark, Delaware, has published pricing and program details positioning itself as a low-cost option for compounded tirzepatide GLP-1 access - though the company’s “most affordable” claim has not been independently verified through full market analysis.

What MEDVi Says It Offers

According to published disclosures, MEDVi facilitates access to GLP-1 medications through a network of independent licensed clinicians and partner pharmacies. The platform operates on a cash-pay basis with no insurance billing, though HSA and FSA payments are accepted.

Published pricing as of March 2026:

• Compounded GLP-1 injections: $179/month (first month), $299/month (refills)
• Compounded GLP-1 oral dissolving tablets: $249/month
• Branded Ozempic: $1,999/month (listed as limited availability, FDA-approved)

MEDVi states the first-month cost covers a physician assessment, personalized plan, metabolic report, guidance, and medication delivery.

Conditional Refund Policy

The company offers a refund guarantee - minus a 25% consultation fee - if a patient completes a minimum five-month commitment, demonstrates program adherence, and achieves no weight loss. Medical consultation fees are described as non-refundable under all circumstances.

Enrollment Process

MEDVi’s platform walks prospective patients through an online evaluation, which the company explicitly states does not create a doctor-patient relationship with MEDVi itself. An independent clinician then reviews the case and makes a prescription decision. MEDVi notes that prescriptions are not guaranteed.

Regulatory Context in 2026

The broader compounded GLP-1 market is operating under increasing regulatory pressure. The FDA resolved its tirzepatide injection drug shortage in December 2024, which formally ended the regulatory basis under which many compounding pharmacies had been producing tirzepatide at scale. FDA enforcement discretion for those compounders has since expired.

In March 2026, the FDA sent warning letters to multiple telehealth companies in the GLP-1 space. Compounded GLP-1 medications - including those offered through platforms like MEDVi - are not FDA-approved finished products and have not been evaluated by the FDA for safety, effectiveness, or quality prior to dispensing.

What to Consider

Patients evaluating compounded tirzepatide programs should be aware that:

• Compounded medications are not FDA-approved and lack the same pre-market safety review as branded drugs.
• Pricing claims in this category are self-reported and not subject to independent auditing.
• The legal environment for compounding pharmacies producing tirzepatide shifted significantly after the FDA shortage resolution.
• Any weight loss results cited by telehealth platforms are typically self-reported.

The full press release, including additional disclosures and program terms, is available at globenewswire.com.